

Supplementary Table 2. Risk factors for hepatocellular carcinoma recurrence in the Group 1 and Group 2 by univariate analysis

	Group 1 (1998–2015) (n = 68)		Group 2 (2016–2020) (n = 62)	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Sex (male)	0.784 (0.316–1.945)	0.600	1.860 (0.360–9.601)	0.459
Age	1.123 (0.949–1.328)	0.179	0.671 (0.429–1.051)	0.081
ICG-R15	1.037 (0.987–1.089)	0.149	0.990 (0.827–1.185)	0.912
ALBI grade				
1	1 (1)		1 (1)	
2	1.452 (0.663–3.179)	0.351	2.189 (0.353–13.579)	0.400
3	-	-	4.107 (0.685–24.642)	0.122
APRI > 1.0	2.342 (1.021–5.372)	0.045	5.042 (0.970–26.199)	0.054
AFP > 40 ng/mL	2.276 (1.026–5.046)	0.043	1.387 (0.267–7.204)	0.697
PIVKA-II > 75 mAU/mL	3.849 (1.381–10.725)	0.010	0.342 (0.076–1.536)	0.161
Extent of operation (major)	0.819 (0.374–1.790)	0.616	0.540 (0.121–2.419)	0.421
Anatomical liver resection	0.746 (0.349–1.597)	0.451	0.375 (0.084–1.683)	0.200
Laparoscopic liver resection	1.845 (0.806–4.227)	0.147	0.913 (0.204–4.094)	0.906
Operation time	1.001 (0.997–1.005)	0.616	0.988 (0.975–1.001)	0.077
Intraoperative RBC transfusion	0.273 (0.037–2.019)	0.203	50.478 (3.156–807.260)	0.006
Blood loss during operation	0.999 (0.997–1.001)	0.272	1.002 (0.999–1.004)	0.264
Hospitalization	1.009 (0.961–1.058)	0.722	1.022 (0.964–1.083)	0.464
Tumor size	0.994 (0.880–1.123)	0.922	1.013 (0.813–1.263)	0.907
Tumor grade 3 or 4	0.209 (0.028–1.541)	0.124	2.970 (0.661–13.344)	0.156
Encapsulation	1.178 (0.444–3.126)	0.742	1.085 (0.130–9.037)	0.940
Microvascular invasion	1.558 (0.719–3.376)	0.261	0.746 (0.144–3.861)	0.727
PVTT	26.933 (4.877–148.720)	<0.001	0.046 (0.001–108.372)	0.723
Satellite nodule	12.975 (3.530–47.695)	<0.001	1.000 (0.001–180.361)	0.977
Free resection margin	1.019 (0.969–1.071)	0.460	0.983 (0.910–1.061)	0.653
Cirrhosis	0.964 (0.421–2.207)	0.931	1.687 (0.377–7.554)	0.494

OR, odds ratio; 95% CI, 95% confidence interval; ICG-R15, indocyanine green at 15 minutes; ALBI, albumin-bilirubin; APRI, aspartate transaminase to platelet ratio index; AFP, alpha-fetoprotein; PIVKA-II, proteins induced by vitamin K absence or antagonist-II; RBC, red blood cell; PVTT, portal vein tumor thrombosis.